Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of

Head and Neck Cancers

(2017) David G. Pfister et al.   Journal of the National Comprehensive Cancer Network

Early Tumor Progression Associated with Enhanced EGFR Signaling with Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer

(2011) A. Argiris et al.   CLINICAL CANCER RESEARCH

Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

(2009) C. H. Chung et al.   ANNALS OF ONCOLOGY

Docetaxel and irinotecan in recurrent or metastatic head and neck cancer

(2009) Athanassios Argiris et al.   CANCER

Nuclear NF- B p65 Phosphorylation at Serine 276 by Protein Kinase A Contributes to the Malignant Phenotype of Head and Neck Cancer

(2009) P. Arun et al.   CLINICAL CANCER RESEARCH

Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death

(2009) C. Li et al.   MOLECULAR CANCER THERAPEUTICS

Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck

(2008) Jill Gilbert et al.   CANCER

Targeted therapy in head and neck cancer

(2008) Corey J. Langer   CANCER

Proteasome Inhibition Activates Epidermal Growth Factor Receptor (EGFR) and EGFR-Independent Mitogenic Kinase Signaling Pathways in Pancreatic Cancer Cells

(2008) C. M. Sloss et al.   CLINICAL CANCER RESEARCH

Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor- B and activator protein-1 related mechanisms

(2008) Z. Chen et al.   MOLECULAR CANCER THERAPEUTICS